Zacks Investment Research
04 Aug 2026, 22:41 UTC · 4h ago
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
04 Aug 2026, 22:41 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Acadia Pharmaceuticals reported quarterly earnings of $0.18 per share, a 200% surprise over the Zacks Consensus Estimate of $0.06. — A significant earnings beat typically drives immediate positive price action for the specific ticker.
+0.60Acadia Pharmaceuticals posted quarterly revenues of $307.96 million, exceeding consensus estimates by 4.81%. — Revenue growth and a beat on the top line support the sustainability of earnings growth.
+0.30Acadia Pharmaceuticals currently holds a Zacks Rank #2 (Buy) based on favorable earnings estimate revisions. — A positive analyst rank suggests institutional support and bullish sentiment for the stock's near-term trajectory.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company reported a significant earnings beat of 200% and revenue that surpassed consensus estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
